Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer
- 1 July 2001
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 68 (1), 9-19
- https://doi.org/10.1023/a:1017903724176
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patientsCancer Letters, 1996
- CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancerBreast Cancer Research and Treatment, 1995
- Breast cancer and clinical utility of CA 15—3 and CEAScandinavian Journal of Clinical and Laboratory Investigation, 1995
- Monoclonal Antibody M3 Used in Tissue Polypeptide–Specific Antigen Assay for the Quantification of Tissue Polypeptide Antigen Recognizes Keratin 18Tumor Biology, 1994
- CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancerClinica Chimica Acta; International Journal of Clinical Chemistry, 1991
- The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigenCancer, 1991
- Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic diseaseCancer, 1989
- Value of CA 15:3 in the follow-up of breast cancer patientsBritish Journal of Cancer, 1987
- Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.JCI Insight, 1985
- DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUESThe Journal of Experimental Medicine, 1965